Nitrate enhances skeletal muscle fatty acid oxidation via a nitric oxide-cGMP-PPAR-mediated mechanism by Ashmore, Tom et al.
RESEARCH ARTICLE Open Access
Nitrate enhances skeletal muscle fatty acid
oxidation via a nitric oxide-cGMP-PPAR-
mediated mechanism
Tom Ashmore1,2, Lee D. Roberts2,3†, Andrea J. Morash1†, Aleksandra O. Kotwica1†, John Finnerty1, James A. West2,
Steven A. Murfitt2, Bernadette O. Fernandez4, Cristina Branco1, Andrew S. Cowburn1, Kieran Clarke5,
Randall S. Johnson1, Martin Feelisch4, Julian L. Griffin2,3 and Andrew J. Murray1*
Abstract
Background: Insulin sensitivity in skeletal muscle is associated with metabolic flexibility, including a high capacity to
increase fatty acid (FA) oxidation in response to increased lipid supply. Lipid overload, however, can result in incomplete
FA oxidation and accumulation of potentially harmful intermediates where mitochondrial tricarboxylic acid cycle capacity
cannot keep pace with rates of β-oxidation. Enhancement of muscle FA oxidation in combination with mitochondrial
biogenesis is therefore emerging as a strategy to treat metabolic disease. Dietary inorganic nitrate was recently shown to
reverse aspects of the metabolic syndrome in rodents by as yet incompletely defined mechanisms.
Results: Herein, we report that nitrate enhances skeletal muscle FA oxidation in rodents in a dose-dependent manner.
We show that nitrate induces FA oxidation through a soluble guanylate cyclase (sGC)/cGMP-mediated PPARβ/δ- and
PPARα-dependent mechanism. Enhanced PPARβ/δ and PPARα expression and DNA binding induces expression of FA
oxidation enzymes, increasing muscle carnitine and lowering tissue malonyl-CoA concentrations, thereby supporting
intra-mitochondrial pathways of FA oxidation and enhancing mitochondrial respiration. At higher doses, nitrate induces
mitochondrial biogenesis, further increasing FA oxidation and lowering long-chain FA concentrations. Meanwhile, nitrate
did not affect mitochondrial FA oxidation in PPARα−/− mice. In C2C12 myotubes, nitrate increased expression of the
PPARα targets Cpt1b, Acadl, Hadh and Ucp3, and enhanced oxidative phosphorylation rates with palmitoyl-carnitine;
however, these changes in gene expression and respiration were prevented by inhibition of either sGC or protein kinase
G. Elevation of cGMP, via the inhibition of phosphodiesterase 5 by sildenafil, also increased expression of Cpt1b, Acadl and
Ucp3, as well as CPT1B protein levels, and further enhanced the effect of nitrate supplementation.
Conclusions: Nitrate may therefore be effective in the treatment of metabolic disease by inducing FA oxidation in
muscle.
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Background
As the largest insulin-sensitive tissue in the body, skeletal
muscle plays a vital role in maintaining glucose homeosta-
sis via the uptake, storage and oxidation of carbohydrate
during the postprandial period. Under fasting conditions,
however, fatty acid (FA) oxidation dominates to satisfy
muscle energy needs whilst sparing glucose and protecting
muscle glycogen reserves [1]. Such flexibility in fuel selec-
tion is a hallmark of metabolically-healthy muscle; indeed,
in human muscle, insulin sensitivity relates strongly to a
capacity to increase FA oxidation in the presence of fat
[2]. Furthermore, the expression of genes involved in oxi-
dative phosphorylation [3] and FA oxidation [4] are down-
regulated in diabetic muscle. The atypical accumulation of
intramyocellular lipids, possibly resulting from impaired
FA oxidation, has been associated with the aetiology of
insulin resistance [5].
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Promotion of muscle FA oxidation thus emerged as a
strategy for the treatment of insulin resistance [6], with
the peroxisome proliferator-activated receptor (PPAR)
transcription factors representing key targets [7]. PPARα
is expressed in liver, heart and skeletal muscle, and when
activated increases the expression of FA oxidation genes
[8]. Meanwhile, PPARβ/δ is ubiquitously expressed, abun-
dantly present in skeletal muscle [8] and, when stimulated,
can reduce obesity and improve insulin sensitivity [9, 10].
In high-fat feeding models, however, enhanced PPAR tar-
get gene expression was associated with increased rates of
incomplete FA oxidation and intra-mitochondrial accu-
mulation of potentially harmful intermediates, e.g. acyl-
CoAs and acyl-carnitines [11]. Indeed, in mice lacking
malonyl-CoA decarboxylase (MCD), decreased mitochon-
drial FA import and catabolism were associated with pro-
tection against glucose intolerance [11].
The concept of mitochondrial overload was thus pro-
posed, in which increased lipid supply and β-oxidation is
not accompanied by sufficient tricarboxylic acid cycle
activity to support complete FA oxidation [12]. PPARγ
co-activator 1α (PGC-1α), a transcriptional co-regulator
that interacts with the PPARs, is considered the master
regulator of mitochondrial biogenesis [13]. Increased
PGC-1α expression following exercise-training pre-
vented lipid-overload-induced mitochondrial deficiency
associated with high-fat feeding, lowering muscle con-
centrations of long-chain acyl-carnitines [14].
Recently, a role has emerged for cyclic guanosine
monophosphate (cGMP) in regulating energy metabol-
ism [15]. In muscle, cGMP stimulated mitochondrial
biogenesis and FA oxidation [16], whilst in white adipose
tissue (WAT), cGMP, acting via cGMP-dependent pro-
tein kinases (PKGs) promoted the browning response
characterised by increased mitochondrial density and
uncoupling protein 1 (UCP1) expression [17, 18].
Dietary nitrate increases plasma cGMP in humans
[19], whilst nitrite increased cGMP levels in some tissues
[20]. Nitrate reversed features of metabolic syndrome in
eNOS−/− mice, including a reduction in body fat and im-
proved glucose homeostasis and insulin sensitivity [21].
Recently, we showed that inorganic nitrate promoted the
browning of WAT via activation of soluble guanylate cy-
clase (sGC) [22]. Moreover, we found that nitrate pre-
vented the downregulation of FA oxidation in the
hypoxic rat heart [23]. The hypoxic suppression of FA
oxidation is commonly seen in both human and rodent
skeletal muscle [24] as well as rat heart [25], and may re-
sult from the hypoxia-inducible factor (HIF)-dependent
suppression of PPARα transcriptional activity and/or
expression, as seen in some tissues [26]. FA oxidation
requires more O2 than glucose oxidation (per ATP
synthesised) and thus this mechanism may spare O2 in
hypoxic tissues. The preservation of FA oxidation in the
hypoxic heart following nitrate supplementation may be
an indirect effect arising from improvements in blood
flow and therefore tissue oxygenation, but notably ni-
trate also increased the FA oxidation capacity of cardiac
mitochondria in normoxic rats [23], perhaps suggesting
a direct effect on metabolic regulation.
We therefore investigated the possible effects of dietary
nitrate on FA oxidation in skeletal muscle, hypothesising
that nitrate would enhance mitochondrial biogenesis and
β-oxidation. We found that nitrate enhances skeletal
muscle FA oxidation in rodents in a dose-dependent man-
ner. Nitrate induces FA oxidation through a sGC/cGMP-
mediated PPARβ/δ- and PPARα-dependent mechanism.
Enhanced PPARβ/δ and PPARα expression and DNA-
binding induces expression of FA oxidation enzymes, in-
creasing muscle carnitine and lowering tissue malonyl-CoA
concentrations, thereby supporting intra-mitochondrial
pathways of FA oxidation and enhancing mitochondrial
respiration. At higher doses, nitrate also induces mitochon-
drial biogenesis, further increasing FA oxidation and lower-
ing long-chain FA concentrations.
Results
Dietary nitrate counteracts the hypoxic suppression of
PGC-1α in skeletal muscle and enhances FA oxidation in
both normoxic and hypoxic skeletal muscle
Since nitrate supplementation prevented the hypoxic
suppression of FA oxidation in rat cardiac muscle [23],
we investigated whether nitrate was similarly protective
in the skeletal muscle of rats exposed to hypoxic condi-
tions (13 % O2) for 14 days compared with rats housed
in a normoxic environment. Rats were supplemented
with either 0.7 mM sodium nitrate or 0.7 mM sodium
chloride (controls) via their drinking water and main-
tained on a standardized quality-controlled (SQC) diet
to normalize micronutrient intake. Nitrate concentra-
tions of food and water were known, thus facilitating
calculation of nitrate intake. No differences were ob-
served in food intake or volumes of water consumed be-
tween any of the groups (data not shown). As shown
previously, consumption of nitrate-supplemented water,
increased nitrate intake by 5- to 7-fold compared with
sodium chloride controls [23].
Nitrate supplementation increased plasma nitrate con-
centrations in both normoxic and hypoxic rats, as shown
previously [23], with no change in nitrite concentrations.
In soleus muscle, hypoxia decreased total NOx, and this
was unaffected by dietary nitrate supplementation (Fig. 1a).
To understand whether nitrate supplementation al-
tered FA oxidation in vivo, we measured total FA con-
centrations (free and conjugated) in whole skeletal
muscle, and found that shorter-chain FAs (here defined
as those < C16, i.e. the shortest FA provided by SQC
diet) were the same in all groups, whilst longer-chain
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FAs (≥C16) decreased by 38 % upon nitrate supplementa-
tion, but increased by 34 % with hypoxic exposure (Fig. 1b).
In nitrate-supplemented hypoxic rats, longer-chain FAs de-
creased by 37 % compared with non-supplemented hypoxic
rats (Fig. 1b), and were comparable with normoxic rats re-
ceiving sodium chloride in their water.
Next, we measured carnitine and acyl-carnitine con-
centrations in the muscle of these rats. Total acyl-
carnitine levels were the same in all groups. However,
the concentration of free carnitine was increased by
54 % following nitrate supplementation, whether in
normoxic or hypoxic rats, whilst hypoxia alone did not
alter carnitine concentrations (Fig. 1c). In humans, car-
nitine loading supports enhanced muscle FA oxidation,
preventing body fat accumulation [27]. An increased ra-
tio of long chain acyl-carnitines to free carnitine has
been described in the hypoxic rat heart in association
with decreased β-oxidation [28], whilst Oram et al. [29]
speculated that high intracellular concentrations of free
carnitine (as found here in nitrate - treated rats) may be
important for selectively channelling fat for oxidation ra-
ther than lipid biosynthesis.
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Fig. 1 Dietary nitrate counteracts the hypoxic suppression of PGC-1α in skeletal muscle and enhances fatty acid oxidation in both normoxic
and hypoxic skeletal muscle. (a) Soleus total nitrogen oxide levels (NOx); (b) Fatty acid profile of soleus tissue divided into≥ C16 (longer-chain)
and < C16 (shorter-chain); (c) Carnitine and acyl-carnitine profile of soleus; (d) Respiration rates and respiratory control ratios with palmitoyl-carnitine
and malate substrates in permeabilized soleus muscle fibres; (e) 3-hydroxyacyl-CoA dehydrogenase activity in soleus tissue; (f) Malonyl-CoA
levels in soleus tissue extracts; (g) Citrate synthase and PGC-1α protein levels in soleus tissue; (h) AMP, ADP and ATP levels in soleus tissue
extracts. Data are represented as mean ± SEM, n = 4–10 per experimental group. * P ≤0.05; ** P ≤0.01; *** P ≤0.001
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To understand how hypoxia/nitrate affected the capacity
of skeletal muscle mitochondria for FA oxidation, respir-
ation rates were measured in permeabilized soleus muscle
fibre bundles with a fatty acyl-carnitine substrate (0.04 mM
palmitoyl-carnitine + 5 mM malate). LEAK state respiration
(i.e. O2 consumption which is not coupled to ADP phos-
phorylation) appeared to be unaffected by either hypoxia or
nitrate alone. However, nitrate supplementation in hypoxia
resulted in LEAK state FA respiration rates that were 64 %
higher than in normoxic/chloride rats (Fig. 1d). In contrast
to our previous finding in heart [23], soleus OXPHOS state
FA respiration rates were unaffected by hypoxia alone;
however, in both normoxic and hypoxic rats, nitrate supple-
mentation resulted in OXPHOS state FA respiration rates
that were 90 % and 81 % higher, respectively, than in
chloride-supplemented controls (Fig. 1d).
We therefore investigated two aspects of mitochon-
drial FA metabolism, namely activity of the β-oxidation
enzyme, 3-hydroxyacyl-CoA dehydrogenase (HOAD),
and tissue concentrations of malonyl-CoA, a negative
regulator of mitochondrial FA import via its inhibitory
effects on the carnitine palmitoyl-transferase (CPT) sys-
tem. Whilst hypoxia did not affect either of these
markers, nitrate supplementation increased HOAD ac-
tivity in normoxic rats (Fig. 1e) and lowered tissue
malonyl-CoA concentrations in both normoxic and hyp-
oxic rats (Fig. 1f ).
In addition to this, we aimed to understand whether the
enhanced FA oxidation capacity following nitrate supple-
mentation could be explained by changes in mitochondrial
density. Protein levels of citrate synthase, a tricarboxylic
acid cycle enzyme and marker of mitochondrial density,
were not significantly altered by either hypoxia or nitrate,
although there was a trend towards decreased levels in
hypoxia that was prevented by nitrate, and a trend to-
wards increased levels in normoxic rats with nitrate
supplementation. Levels of PGC-1α, however, were 60 %
lower in hypoxic muscle compared with that of chloride-
supplemented normoxic animals and this was prevented
by nitrate supplementation (Fig. 1g). Interestingly, PGC-
1α levels were 50 % higher in the muscle of nitrate-
supplemented normoxic rats compared with control
animals (P ≤0.001). Thus, although the changes in
PGC-1α were not associated with significant changes
in citrate synthase activity, our findings nevertheless
suggested that nitrate may exert effects on mitochon-
drial biogenesis via PGC-1α, and that this might be-
come apparent with higher doses of nitrate.
Finally, to understand the energetic implications of
these changes, we measured AMP, ADP and ATP levels
in the soleus of these rats. Hypoxic exposure decreased
ATP and increased AMP levels, indicating impaired en-
ergetics, whilst nitrate supplementation prevented this
(Fig. 1h).
Dietary nitrate enhances FA oxidation and mitochondrial
biogenesis in the skeletal muscle of normoxic animals in
a dose-dependent manner
Since nitrate supplementation was found to enhance FA
oxidation in normoxic skeletal muscle, we focused on
normoxic rats alone in order to establish whether the
different effects observed on mitochondrial biogenesis
and FA oxidation are dose dependent. Rats received the
same SQC diet as before and water supplemented with
0 mM (control), 0.35 mM (low), 0.7 mM (medium), and
1.4 mM (high) sodium nitrate. As such, the medium
dose group was equivalent to that received by the
nitrate-supplemented normoxic group in the hypoxia
study. Nitrate supplementation did not affect food or
water intake, and body weight was unaffected (Table 1).
Nitrate intake increased dose-dependently across the
groups (Table 1), as did plasma nitrate levels; however,
plasma nitrite levels only increased in the high dose
group, as shown previously [30].
Next, we measured total FA concentrations in whole
skeletal muscle, and found that shorter-chain FAs were
the same in all groups, whilst longer-chain FAs (those ≥
C16) decreased dose-dependently with nitrate supple-
mentation (Fig. 2a), suggesting that nitrate increased FA
catabolism in a dose-dependent manner. Correspond-
ingly, oxygen consumption of permeabilized soleus
muscle fibres with 0.04 mM palmitoyl-carnitine and
5 mM malate also increased with nitrate supplementa-
tion (Fig. 2b), with LEAK state respiration increasing
dose-dependently, yet OXPHOS respiration peaking at
the medium dose (72 % greater than controls) and
remaining elevated at the high dose.
To understand whether these effects might be attrib-
uted to changes in mitochondrial density or intra-
mitochondrial changes, we measured citrate synthase
and HOAD activities in whole skeletal muscle lysates
from these rats. Citrate synthase (CS) activity was not al-
tered by the low or medium doses of nitrate, but was
2.9-fold higher in rats receiving high-dose nitrate supple-
mentation compared with controls (Fig. 2c). Meanwhile,
Table 1 The effects of 18 days supplementation with low
(0.35 mM), medium (0.7 mM) and high (1.4 mM) doses of
dietary nitrate on food, water and nitrate intakes, and body
weight in rats, data = mean ± SEM, n = 5–6 per group
Control Low Medium High
Food intake (g/day) 30 ± 1 30 ± 1 30 ± 1 30 ± 1
Water intake (mL/day) 30 ± 3 35 ± 2 36 ± 3 32 ± 3
Calculated intake
Nitrate (mg/kg/day) 1 ± 1 5 ± 2 8 ± 2 13 ± 1
Body weight
Start (g) 265 ± 5 268 ± 6 270 ± 4 271 ± 3
End (g) 406 ± 8 420 ± 13 415 ± 9 404 ± 4
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HOAD activity showed a similar pattern, with no effect
of low or medium doses of nitrate supplementation, but
86 % higher activity at the highest dose of nitrate
(Fig. 2d). Thus, whilst the effects of high-dose nitrate
supplementation might be attributed, at least in part, to
mitochondrial biogenesis, it appears that at lower doses
there is nevertheless an enhanced capacity for FA oxida-
tion which is driven by intra-mitochondrial changes.
Therefore we further investigated the nitrate-enhanced
FA oxidation in mitochondrial isolates using 14C-palmi-
tate oxidation and CPT1 activity. 14C-palmitate oxida-
tion per unit of mitochondrial protein was increased by
nitrate supplementation, though this only reached statis-
tical significance at the highest dose of nitrate (Fig. 2e).
CPT1 activity, however, was increased by low and
medium doses of nitrate, peaking at the lowest dose of
nitrate used here and not reaching statistical significance
at the highest dose (Fig. 2f). Tissue levels of malonyl-CoA,
a negative regulator of CPT1, were decreased by 60–70 %
at all doses of nitrate (Fig. 2g). This appeared to be due to
an upregulation of MCD, since protein levels of MCD
were elevated by nitrate supplementation in a similar
fashion to CPT1 activity and were inversely related to
tissue malonyl-CoA, peaking in the skeletal muscle of
A
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Fig. 2 Dietary nitrate enhances fatty acid oxidation and mitochondrial biogenesis in skeletal muscle. (a) Fatty acid profile of soleus tissue divided
into≥ C16 (longer-chain) and < C16 (shorter-chain); (b) Respiration rates with palmitoyl-carnitine and malate substrates in permeabilized soleus muscle
fibres; (c) Citrate synthase activity in soleus tissue; (d) 14C-Palmitate oxidation rates in mitochondrial isolates from soleus muscle; (e) 3-hydroxyacyl-CoA
dehydrogenase activity in soleus tissue; (f) CPT1 activity in mitochondrial isolates from soleus muscle; (g) Malonyl-CoA levels in soleus tissue
extracts; (h) Malonyl-CoA decarboxylase protein levels in soleus tissue. Data are represented as mean ± SEM, n = 4–6 per experimental group.
* P ≤0.05; ** P ≤0.01; *** P ≤0.001
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the low-dose-supplemented group and failing to reach
significance at the higher dose (Fig. 2h).
Dietary nitrate enhances FA oxidation in skeletal muscle
via enhanced PPARα and PPARβ/δ transcriptional activity
Thus far, our data suggested that nitrate exerts dose-
dependent effects on skeletal muscle FA oxidation, with
intra-mitochondrial effects predominating at lower
doses, including a release of inhibition on mitochondrial
FA import via the CPT system, and a stimulation of
mitochondrial biogenesis at higher doses. We next
sought to investigate the downstream signalling/effector
pathways mediating these nitrate-induced effects.
NO, a putative product of nitrate reduction, is
known to increase levels of the secondary messenger
cGMP in tissue; therefore, we first measured cGMP
and cAMP levels in the soleus of the rats. We found
that nitrate elevated cGMP in a dose-dependent man-
ner, whereas cAMP was unaffected by nitrate at any
dose (Fig. 3a).
Since cGMP activates PPAR signalling [31] and
many FA oxidation enzymes and regulators are tran-
scriptional targets of PPARα and PPARβ/δ, we investi-
gated the mechanism of these dose-dependent effects,
focusing on PPAR-driven transcription. The expres-
sion of PPARα and PPARβ/δ in the soleus of rats
supplemented with nitrate was analysed. We found
that PPARα levels increased dose-dependently with
nitrate supplementation, being 1.8-fold higher in the
soleus of high-dose rats, compared with controls. Ex-
pression of PPARβ/δ was also increased with nitrate
supplementation but peaked at the low dose, and was
not significantly elevated in the soleus of high-dose
rats (Fig. 3b). Correspondingly, PPARα DNA-binding
activity increased dose-dependently with nitrate,
whilst that of PPARβ/δ was enhanced by nitrate but
peaked at the lowest dose (Fig. 3c). It therefore ap-
pears that the dose-dependence of the effects we pre-
viously observed relate to the divergent downstream
effects of the different PPAR isoforms.
To further confirm that the effects of nitrate occur
via PPARα activation, we switched our attention to
PPARα−/− mice, which, along with wild-type controls,
were supplemented with 0.7 mM sodium nitrate (or
sodium chloride) for 14 days. In agreement with stud-
ies in rats, we found that nitrate increased palmitoyl-
carnitine respiration in the OXPHOS state by 38 % in
wild-type mice. In PPARα−/− mice, palmitoyl-carnitine
respiration was lower than in wild-type mice, as ex-
pected, and was not affected by nitrate supplementa-
tion (Fig. 3d). Nitrate increased PPARα DNA-binding
activity in wild-type mice, but PPARβ/δ DNA-binding
activity did not increase in PPARα−/− or wild-type
mice with nitrate supplementation (Fig. 3e).
Nitrate enhances FA oxidation capacity via NO-cGMP-PKG
in C2C12 myotubes
Our data therefore suggested a role for enhanced PPARα
transcriptional activity in the effects that nitrate exerts
on FA oxidation. We hypothesized that this might occur
via NO activation of sGC, leading to elevation of cGMP
and hence downstream activation of PKG. We therefore
sought to test this proposed mechanism in C2C12 myo-
blasts exposed to different concentrations of sodium
nitrate.
Following induction of differentiation, cells expressed
muscle differentiation markers (MyoD, Tnni1 and Tnni2)
after 6 days (Fig. 4a), and this was unaffected by any of
the experimental conditions we later used; i.e. supple-
mentation with nitrate alone at either 50 or 500 μM
(Fig. 4b) or nitrate in the presence of inhibitors for sGC
or PKG (Additional file 1: Figure S1). Nitrate supple-
mentation at 50 μM did not alter LEAK state respiration
in digitonin-permeabilized cells in the presence of
palmitoyl-carnitine (Fig. 4c); however, this rate was en-
hanced by 500 μM nitrate – an effect prevented by both
sGC and PKG inhibition (Fig. 4d). OXPHOS state respir-
ation was also unaffected by 50 μM nitrate; however, both
sGC and PKG inhibition decreased this respiration rate in
C2C12 cells, whether supplemented with nitrate or not
(Fig. 4e). At 500 μM, nitrate did enhance palmitoyl-
carnitine respiration in the OXPHOS state (Fig. 4f) – an
effect abrogated by sGC and PKG inhibition.
We proceeded to investigate the effects of nitrate sup-
plementation on the expression of FA oxidation enzymes
and other mitochondrial proteins in C2C12 cells. We
found that expression of Cpt1b, Acadl and Hadh (en-
coding CPT1B, long-chain acyl-CoA dehydrogenase and
HOAD, respectively), was enhanced by 500 μM, but not
50 μM, nitrate supplementation (Fig. 5a), as was the ex-
pression of Ucp3 and Cycs (encoding uncoupling protein
3 and cytochrome c, respectively), whilst expression of
the complex I subunit Ndufs1 was enhanced at both 50
and 500 μM nitrate (Fig. 5b). The effects of nitrate were
time-dependent, reaching significance after 6 days of dif-
ferentiation (Additional file 2: Figure S2). Notably, inhib-
ition of sGC (Figs. 5c,d) and PKG (Figs. 5e,f ) abolished
all of these effects, confirming that the mechanism
underlying the effects of nitrate on enhanced PPAR ex-
pression and transcriptional activity are mediated via the
NO-cGMP-PKG signalling pathway.
To further confirm the role of cGMP in mediating the
effect of nitrate on FA oxidation, we treated C2C12 cells
with 500 μM nitrate and/or 1 μM of the cGMP-specific
phosphodiesterase 5 inhibitor, sildenafil, which prevents
cGMP breakdown. As before, 500 μM nitrate increased
expression of Ucp3, Acadl and Cpt1b, and a similar in-
crease in expression of all three targets was seen with
1 μM sildenafil alone (Fig. 6a). As expected, 500 μM
Ashmore et al. BMC Biology  (2015) 13:110 Page 6 of 17
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Fig. 3 (See legend on next page.)
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Fig. 4 Nitrate enhances fatty acid oxidation capacity via NO-cGMP-PKG in C2C12 myotubes. (a) Muscle differentiation marker expression in C2C12
myoblasts cultured and differentiated over 6 days; (b) Muscle differentiation marker expression in C2C12 myocytes cultured and differentiated over
6 days in the presence of 0, 50 and 500 μM nitrate. See also Additional file 1: Figure S1. LEAK state respiration of palmitoyl-carnitine and malate
substrates in permeabilized C2C12 myotubes cultured and differentiated over 6 days in the presence of (c) 0 or 50 μM nitrate or (d) 0 or 500 μM
nitrate, in the presence or absence of sGCi (ODQ, 1 μM) or PKGi (KT5823, 1 μM). OXPHOS state respiration of palmitoyl-carnitine and malate substrates
in permeabilized C2C12 myotubes cultured and differentiated over 6 days in the presence of (e) 0 or 50 μM nitrate or (f) 0 or 500 μM nitrate, in the
presence or absence of sGCi (ODQ, 1 μM) or PKGi (KT5823, 1 μM). Data are represented as mean ± SEM, n = 4 repeats per condition. * P ≤0.05;
** P ≤0.01; *** P ≤0.001
(See figure on previous page.)
Fig. 3 Dietary nitrate enhances fatty acid oxidation in skeletal muscle via enhanced PPARα and PPARβ/δ activity. (a) Levels of cAMP and cGMP in
soleus extracts from rats supplemented with control (0 mM), low (0.35 mM), medium (0.7 mM) and high (1.4 mM) doses of dietary nitrate; (b)
PPARα and PPARβ/δ expression in soleus tissue; (c) PPARα and PPARβ/δ DNA-binding in nuclear extracts of soleus; (d) Respiration rates and
respiratory control ratio with palmitoyl-carnitine and malate substrates in permeabilized soleus muscle fibres from wild-type and PPARα−/− mice;
(e) PPARα and PPARβ/δ DNA-binding in nuclear extracts of soleus from wild-type mice and PPARα−/− mice. Data are represented as mean ± SEM,
n = 3–8 per experimental group. * P ≤0.05; ** P ≤0.01; *** P ≤0.001
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nitrate and 1 μM sildenafil in combination, acting to
both increase cGMP production and decrease cGMP
breakdown, produced a greater increase in expression of
all three targets than either treatment alone (Fig. 6a).
Finally, we set out to confirm that the changes in Cpt1b
expression were reflected at the protein level. Both
500 μM nitrate and 1 μM sildenafil increased CPT1B pro-
tein concentration in C2C12 cells, with a greater increase
in CPT1B seen when nitrate and sildenafil were adminis-
tered in combination (Fig. 6b). Meanwhile, treatment with
the sGC inhibitor, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-
1-one (ODQ), prevented the effect of nitrate on CPT1B
concentration (Fig. 6b).
Discussion
Herein, we report that moderate doses of dietary inor-
ganic nitrate increase the capacity for FA oxidation in
skeletal muscle. The mechanism is dose-dependent, with
increased expression and transcriptional activity of
PPARβ/δ and PPARα occurring at lower nitrate concen-
trations, upregulating intra-mitochondrial pathways of
FA oxidation, relieving inhibition of the CPT shuttle by
malonyl-CoA via the upregulation of MCD, and increas-
ing muscle carnitine concentrations. Notably, the same
doses of nitrate did not increase FA oxidation in the
muscle of PPARα−/− mice. Increased mitochondrial vol-
ume density was observed at the highest dose of nitrate
used in this study, supporting the capacity of muscle for
complete FA oxidation. The underlying mechanism in-
volves enhanced NO bioavailability, which activates sGC
to increase muscle cGMP concentrations, subsequently
activating PKG and leading to PPARα and (at higher
doses) PGC-1α upregulation (Fig. 7). Indeed, in myo-
cytes, inhibition of sGC or PKG prevented the nitrate-
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Fig. 5 Nitrate enhances the expression of fatty acid oxidation enzymes and other mitochondrial proteins via NO-cGMP-PKG in C2C12 myotubes.
(a) Cpt1b, Acad1 and Hadh, and (b) Ucp3, Cycs and Ndufs1 expression in C2C12 myotubes cultured and differentiated over 6 days in the presence
of 0, 50 and 500 μM nitrate, (c and d) in the presence and absence of sGCi (ODQ, 1 μM), and (e and f) in the presence and absence of PKGi
(KT5823, 1 μM). Data are represented as mean ± SEM, n = 4 repeats per condition. * P ≤0.05; ** P ≤0.01; *** P ≤0.001
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driven upregulation of PPARα-target genes and other
mitochondrial proteins.
The excellent agreement in results across different
techniques, experimental models and platforms provided
a solid foundation for our study and allowed not only a
comprehensive description of the effects of nitrate on
muscle FA oxidation but also the elucidation of the
underlying mechanism. For instance, the use of isolated
rat muscle mitochondria allowed us to consider the
changes in intra-mitochondrial FA oxidation pathways,
whilst the use of permeabilized muscle fibres, protein
levels and enzyme activities provided a picture of FA
oxidation capacity at the tissue level. Meanwhile, tar-
geted analysis of tissue metabolites (FA methyl esters
to measure total FA content, carnitines/acyl-carnitines
to indicate mitochondrial FA import, AMP/ADP/ATP
to indicate energetic status, nitrogen oxides, and
malonyl-CoA) supports the notion that changes in cap-
acity measured ex vivo correspond to changes in FA
oxidation in vivo. In order to establish underlying
mechanisms, we again employed a number of ap-
proaches, including DNA-binding assays in nitrate-
supplemented rats and wild-type and PPARα−/− mice,
plus cell respiration and gene expression analysis in
cultured myocytes alongside the use of targeted inhibi-
tors of upstream actors in our proposed pathway (sGC
and PKG). The finding that nitrate enhanced FA oxida-
tion in cultured myocytes indicates that effects are in-
dependent of changes in blood flow, and thus oxygen
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Fig. 6 Nitrate and sildenafil cumulatively increase the expression of
fatty acid oxidation enzymes and other mitochondrial proteins, and
increase CPT1B protein levels. (a) Ucp3, Acad1 and Cpt1b expression
in C2C12 myotubes differentiated in the presence of 500 μM nitrate,
1 μM sildenafil, or both nitrate and sildenafil in combination. (b) CPT1B
protein levels in C2C12 cells exposed to 500 μM nitrate, 1 μM sildenafil,
nitrate and sildenafil in combination, 1 μM ODQ, and nitrate and ODQ
in combination. Data are represented as mean ± SEM, n = 3 repeats per
condition. * P ≤0.05; ** P ≤0.01; *** P ≤0.001
Fig. 7 Schematic outlining the proposed mechanism underlying the
effect of dietary nitrate on fatty acid (FA) oxidation and mitochondrial
biogenesis in skeletal muscle. Nitrate (NO3
−) is sequentially reduced to
nitrite (NO2
−) and nitric oxide (NO), which activates soluble guanylate
cyclase. Thus, nitrate dose-dependently increases cellular cGMP,
activating protein kinase G. At low doses of nitrate, PPARβ/δ levels
increase, increasing expression of CPT1 and lowering malonyl-CoA,
increasing FA oxidation. At intermediate doses of nitrate, induction of
PPARα augments these changes and increases carnitine levels, further
increasing FA oxidation. Meanwhile, PPARβ/δ expression is repressed
by PPARα activation. At higher doses, increased expression of 3-
hydroxyacyl CoA dehydrogenase occurs alongside elevated citrate
synthase, indicating mitochondrial biogenesis, which further enhances
muscle capacity for FA oxidation
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delivery, secondary to the vasodilatory effects of nitro-
gen oxides.
As with our previous studies of the effects of dietary ni-
trate on tissue metabolism and oxygen delivery [22, 23, 30],
our use of a SQC diet and deionized water allowed us to
acutely manipulate micronutrient concentrations in rats
and mice, whilst accurately monitoring nitrate intake
without restricting food or water intake. The nitrate
interventions used were relatively short-term in duration
(14 – 18 days) and although we would expect this to re-
flect the long-term effects of nitrate supplementation it
would be worth confirming this. Whilst we have shown
that nitrate still exerts these effects in hypoxic rats, it
would be interesting to additionally investigate and assess
the effectiveness of these mechanisms during other meta-
bolic stresses (e.g. high-fat feeding, diabetes or exercise).
The effects of nitrate and hypoxia on FA oxidation
and mitochondrial biogenesis appear to be tissue-
specific. For instance, whilst we previously found that ni-
trate supplementation (at the medium dose used herein)
modestly increased the capacity of rat cardiac mitochon-
dria to oxidise palmitoyl-carnitine (by 25 %) and pre-
vented the hypoxic suppression of FA oxidation [23],
there was no such hypoxic suppression apparent in the
soleus, and instead the dominant effect of nitrate was to
double the capacity for palmitoyl-carnitine respiration.
In the mammalian heart, FA oxidation is the major
source of ATP generation under normal conditions [32],
whereas skeletal muscle utilises carbohydrate and FA
more evenly [33], so there is more scope to increase FA
oxidation in skeletal muscle. It is perhaps surprising that
there was no significant loss of mitochondria and/or FA
oxidation capacity in the hypoxic rat soleus, given that
such effects are well-documented in human skeletal
muscle following sustained exposure to hypoxia [34–36];
however, it should be noted, this does not occur in
humans with more acute exposure [35, 37]. The relative
preservation of FA oxidation in hypoxia may also be a
particular feature of the soleus, a highly-oxidative, type 1
muscle, which contrasts with the mixed fibre-type vastus
lateralis commonly biopsied for use in human studies. It
is notable, however, that whilst there are variations in
mitochondrial function between different muscles of the
mouse hindlimb, it is mouse soleus that most closely re-
sembled human quadriceps in terms of the coupling
control of electron transport during FA oxidation [38].
Meanwhile, in WAT (and primary adipocytes), nitrate
and hypoxia act synergistically in promoting the browning
response, with the greatest expression of PGC-1α, CPT1
and, particularly, UCP1 occurring under hypoxic/nitrate-
supplemented conditions [22]. It is possible that hypoxia
systemically augments the production of NO from dietary
nitrate by sequential reduction, with the expression and
nitrate reductase activity of xanthine oxidoreductase
increasing under hypoxic conditions [39]. The increased
availability of NO in low oxygen conditions may, however,
be offset in skeletal muscle and heart, by the HIF-
dependent downregulation of PPARα and PGC-1α [34],
preventing downstream metabolic effects. Indeed, in the
absence of hypoxia, there are striking parallels between
the effects of nitrate on rat WAT and skeletal muscle, par-
ticularly regarding the dose-dependency of the changes
observed. For instance, citrate synthase activity increased
in both tissues in a dose-dependent manner, whilst CPT1
protein/activity peaked at the lowest dose of nitrate used
(0.35 mM) as did UCP1 in WAT [22].
The dose dependent effects of nitrate we report herein
may be attributable to differential effects on the expres-
sion of PPAR isoforms and PGC-1α. At the lowest dose
of nitrate used, there was no induction of PPARα, but
the greatest expression of PPARβ/δ and enhanced
PPARβ/δ-DNA binding, alongside elevated CPT1 activ-
ity. Whilst this dose was not associated with a significant
increase in mitochondrial palmitoyl-carnitine respiration
or muscle 14C-palmitate oxidation ex vivo, we saw de-
creased long-chain FAs in the muscles of these rats, sug-
gesting more subtle effects on in vivo FA oxidation at
this dose. At the medium dose of nitrate, PPARα expres-
sion was induced in addition to PPARβ/δ and this re-
sulted in increased palmitoyl-carnitine respiration and
14C-palmitate oxidation, alongside a larger decrease in
total long-chain FAs. Whilst there was no increase in cit-
rate synthase activity at this dose, PGC-1α levels were
increased. At the highest dose of nitrate used, PPARβ/δ
expression and PPARβ/δ-DNA binding fell below that of
lower doses, though PPARα expression and DNA-bind-
ing activity was highest. Our data suggest a suppression of
PPARβ/δ by PPARα activation, an effect previously de-
scribed in rat brain astrocytes [40]. Alongside an increase
in mitochondrial density at the highest dose, the elevated
PPARα levels supported the greatest rate of 14C-palmitate
oxidation and resulted in the lowest levels of total
long-chain FAs, although, interestingly, mitochondrial
palmitoyl-carnitine respiration (representing β-oxidation)
was no higher than at the medium dose. These findings
show similarities with high-fat fed mice that have under-
taken exercise-training to elevate PGC-1α expression [14].
There was surprisingly good agreement between the effects
of nitrate at these doses between rats and mice in the
present study. NO production rates [41] and circulating ni-
trate/nitrite concentrations [42] are similar between rats
and humans, but lower than those in mice [43]. Our data,
however, demonstrate that nitrate supplementation at the
intermediate dose results in increased PPARα DNA-
binding (though not PPARβ/δ DNA-binding) in mice too.
The intermediate dose of nitrate used herein matches
that shown to have metabolic effects in studies of hu-
man muscle [44] and which can be achieved in humans
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via a slight modification of the diet, e.g. via a modest in-
crease in consumption of leafy green vegetables such as
spinach and beetroot [45]. In humans, this dose was
found to decrease the oxygen cost of exercise [46], im-
prove mitochondrial efficiency via a lowering of LEAK
state respiration [44], and to lower whole-body resting
metabolic rate [45]. These effects were associated with
decreased muscle expression of the putative uncoupler
adenine nucleotide translocase, but also a strong trend
towards decreased UCP3 expression [44]. Our findings
in rodents do seem to contradict some of these effects in
humans. However, beyond the obvious difference in spe-
cies, some other key differences between the studies
should be noted, along with some similarities. Firstly,
our rats were maintained on a standardised version of
normal rat chow, which is low in fat content, whereas
the humans essentially consumed a regular diet, albeit
avoiding foodstuffs high in nitrate [44, 45]. Therefore,
rats would have conceivably had a greater scope to in-
crease their capacity for FA oxidation compared to
humans as PPAR activation via the diet would have been
lower at baseline, whilst the rats were also sedentary and
would therefore be expected to have relatively low
muscle mitochondrial contents at baseline. In addition,
the mitochondrial respiration studies of human vastus
lateralis employed pyruvate and malate as substrates
[44], as opposed to the FA derivative palmitoyl-carnitine
that we used here, and as such they were not optimised
to see differences in FA oxidation. Interestingly, however,
although LEAK state respiration increased in the rats
with nitrate supplementation in our study, respiratory
control ratios (OXPHOS/LEAK) did in fact increase in
both rats and wild-type mice, indicating improved mito-
chondrial coupling and thus enhanced efficiency with a
higher rate of oxidative phosphorylation. Finally, we have
not measured whole-body oxygen consumption in these
rats, and it would be interesting to do so, but previous
work from our group with the livers of rats receiving the
same doses of nitrate showed a dose-dependent fall in
HIF-1 activation, suggesting a better matching of oxygen
supply and demand despite decreased circulating haemo-
globin, and thus possibly indicating decreased oxygen con-
sumption or improved mitochondrial efficiency, at least in
this tissue [30].
Our finding of enhanced skeletal muscle FA oxidation
capacity with moderate consumption of dietary nitrate
now deserves further investigation in healthy human sub-
jects, as well as those with metabolic disease, with further
investigation in animal models of metabolic syndrome. A
similar dose of nitrate was previously found to have anti-
obesity and insulin-sensitizing effects in the eNOS−/−
mouse, which exhibits a metabolic syndrome-like pheno-
type [21], and it would be interesting to see whether
nitrate exerts similarly-protective effects in obese and
insulin-resistant rodents where the primary defect is not
one of NO-production, e.g. diet-induced obesity or leptin-
deficiency/resistance. In combination with our previous
finding that nitrate stimulates the browning of WAT, how-
ever, our work suggests that nitrate supplementation holds
promise as a potential therapy for metabolic disease.
Conclusions
We have found that a moderate dose of dietary nitrate
enhances skeletal muscle FA oxidation capacity by pro-
moting intra-mitochondrial pathways of FA oxidation
and, at higher doses, mitochondrial biogenesis. The
underlying mechanism is dose-dependent, and occurs
via enhanced NO bioavailability and increased muscle
cGMP levels, leading to the upregulation of PPARα and
PGC-1α.
Methods
All procedures involving live animals were carried out by a
licence holder in accordance with UK Home Office
regulations, and underwent review by the University of
Cambridge Animal Welfare and Ethical Review Committee.
Some, but not all, of the rats used in this work were also
used in separate, but parallel studies of oxygen consump-
tion by other tissues [22, 23] and oxygen delivery [30],
with a view to reducing the total numbers of animals used
in accordance with UK Home Office best practice. Where
relevant data (e.g. nitrate intakes and plasma [NOx]) has
been reported previously, we refer to the previous paper
and thus have not duplicated data.
Animal studies
Male Wistar rats (273 ± 2 g; n = 40) acquired from
Charles River (UK) were maintained on a standardized
quality-controlled chow to normalize micronutrient
levels (RM1(E)SQC, Special Diets Services, UK; 55 %
carbohydrate, 3 % fat, 15 % protein). After 12 days
acclimatization, animals received either 0.7 mM NaNO3
(nitrate group) or NaCl (control group; both ultra-pure,
Sigma-Aldrich) in distilled water (n = 20/group). After
4 days, half of each group were transferred to hypoxia
chambers (13 % O2; 20 air changes/hr) (PFI Systems Ltd,
UK; n = 10/group). All animals remained in these condi-
tions, with ad libitum access to food and NaNO3/NaCl-
supplemented water for 14 days. Animals were housed
pairwise in conventional cages at controlled humidity
and temperature with a 12-h light/dark cycle.
To establish a dose–response study, male Wistar rats
(269 ± 2 g; n = 24) were housed under normoxia conditions
otherwise identical to those above, on standardized rodent
chow, with access to distilled water ad libitum. After 12 days
acclimatization, rats received distilled water or water sup-
plemented with NaNO3 (0.35, 0.7, 1.4 mM; n = 6/group) ad
libitum for 18 days. Wild-type 129Ev/Sv and PPARα−/−
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mice (2–3 months of age), a gift of Dr Frank Gonzalez
(National Cancer Institute, Bethesda MD, USA), were
housed under identical conditions, and received distilled
water or water supplemented with 0.7 mM NaNO3 (n = 8/
group) ad libitum for 14 days.
C2C12 studies
C2C12 cells (Sigma-Aldrich) were cultured in 1 mL
Dulbecco’s Modified Eagle’s Medium (DMEM; 4.5 g/L
glucose, L-glutamine, NaHCO3 and pyridoxine-HCl) sup-
plemented with 10 % fetal bovine serum and 1× penicillin/
streptomycin (100 U/mL and 100 μg/mL, respectively) in
12-well plates (Millipore, USA) at 37 °C in 5 % CO2.
Medium was changed daily, and upon reaching conflu-
ence, cells were maintained in differentiation medium for
6 days (DMEM supplemented with 2 % horse serum and
1× penicillin/streptomycin). Differentiation medium was
changed daily for the first 3 days, and every 12 h for the
remaining 3 days. After 2 days of differentiation, cells were
also supplemented with 0, 50 or 500 μM nitrate. In inhibi-
tor experiments, cells were additionally incubated with ei-
ther 1 μM ODQ (sGC inhibitor) for the final 2 days of
differentiation, 1 μM KT5823 (PKG inhibitor; Santa Cruz
Biotechnology Inc., USA) for the final 3 days, 1 μM silden-
afil (cGMP-specific phosphodiesterase 5 inhibitor) for the
final 4 days, or 1 μL dimethyl sulfoxide as control. In the
time-course study of nitrate effects on selected gene ex-
pression, cells were supplemented with 500 μM nitrate at
2, 4 and 6 days before collection, whilst ‘0 days’ received
no nitrate and acted as a control.
To produce sufficient cells for CPT1B protein quantifi-
cation, C2C12 cells were instead grown and differentiated
in collagen I-coated T75 flasks (Millipore, USA), using the
same medium-change procedure and nitrate/inhibitor
concentrations as above. Cells were lysed with 1 mL
radio-immunoprecipitation buffer (Sigma-Aldrich) sup-
plemented with protease inhibitor (Complete mini prote-
ase inhibitor cocktail, Roche, Germany) and the protein
concentration quantified using the Pierce BCA Protein
Assay kit (Thermo Scientific).
For respirometry analysis, the medium was removed and
0.5 mL trypsin (10× trypsin-EDTA, Invitrogen) added to
separate cells from the well, 0.5 mL differentiation medium
was added to each well to inactivate trypsin, and the result-
ing solution pipetted into a microcentrifuge tube. From the
microcentrifuge tubes, 100 μL of solution were added to
900 μL PBS and the cell number counted. Tubes containing
the remaining cells were centrifuged at 600 × g for 5 min to
pellet the cells; the medium was removed and the pellet
gently resuspended in 600 μL respiration medium.
Nitrate and nitrite levels
Nitrate was quantified using a dedicated HPLC system
(ENO-20, Eicom; Tokyo, Japan), employing sequential
ion chromatography, online reduction to nitrite using a
cadmium column, and post-column-derivatization with
a modified Griess reagent, as described in previously
published protocols [47].
Metabolic profiling
Aqueous and organic metabolites were extracted from
soleus muscle as described previously [23].
Aqueous extracts were reconstituted in 100 μL 70:30
acetonitrile:water before metabolites were measured using
hydrophilic interaction liquid chromatography-mass spec-
trometry. Multiple reaction monitoring in positive ion
mode was used with the following optimised mass transi-
tions: malonyl-CoA, 854.0 > 347.1; cGMP, 346.1 > 152.1;
cAMP, 330.1 > 136.1; AMP, 348.03 > 135.90; ADP, 427 >
135.90; ATP, 507.91 > 135.90. Malonyl-CoA, cGMP,
cAMP, AMP, ADP and ATP had separately optimised
declustering potentials and collision energies as follows:
41 V, 23 eV; 81 V, 41 eV; 71 V, 31 eV; 95.0 V, 18 eV; 30.0 V,
30.0 eV; 30.0 V, 30.0 eV; and 35.0 V, 15.0 eV, respectively.
Other optimisation parameters common to each species
were ion spray voltage 5.5 kV and temperature 500 °C. A
5-μL injection volume was analysed on a 5500 QTRAP
mass spectrometer (AB Sciex, Toronto, Canada) attached
to an Acquity ultra-performance liquid chromatography
system (UPLC; Waters Corporation, MA, USA). Chroma-
tographic separation was achieved using a 100 mm×
2.1 mm× 1.7 μm BEH amide hydrophilic interaction liquid
chromatography column (Waters) with 30 % aqueous con-
taining 10 mM ammonium acetate (pH 9 with ammonium
hydroxide) increasing to 50 % aqueous over 5 min at a flow
rate of 600 μL/min. The column was re-equilibrated for a
further 3 min at cessation of the gradient. Malonyl-CoA
was normalised to a universally 13C- and 15N-labelled glu-
tamate internal standard (Cambridge Isotope Laboratories
Inc., USA) and compared with a 6-point malonyl-CoA
calibration line over the 10 nM to 50 μM concentration
range due to non-linearity at low nanomolar concentra-
tions. cGMP data were normalised to the same internal
standard and compared with an 8-point cGMP calibration
line with concentrations ranging from 1 nM to 50 μM.
cAMP data were normalised to the same internal standard
and compared with an 8-point cAMP calibration line with
concentrations ranging from 1 nM to 50 μM.
Organic extracts were reconstituted in 400 μL 1:1
chloroform:methanol and mixed thoroughly. When fully
dissolved, 100 μL of each sample were transferred to a
3.5 mL glass vial; the remaining 300 μL were dried over-
night in a fume hood and frozen at −20 °C and 650 μL
of 1:1 chloroform:methanol, D25-tridecanoic acid as in-
ternal standard to a final concentration of 21 μM, and
125 μL 10 % BF3/methanol were added to each sample.
This derivatisation procedure converts FAs to fatty acid
methyl esters. The vials were then vortexed, and
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incubated for 90 min at 80 °C. After cooling, 500 μL
HPLC-grade water and 1 mL hexane were added, and
the vials thoroughly mixed by vortexing. The upper, or-
ganic, layer was transferred to a 2 mL GC vial and
allowed to dry overnight in a fume hood.
FAME samples were reconstituted in 200 μL hexane
and a 2 μL injection run on a Trace GC Ultra coupled to a
Trace DSQ II single quadrupolar mass spectrometer
(Thermo Scientific). The oven parameters were as follows:
initial temperature 60 °C; ramp 15 °C/min to 150 °C; and
ramp 2 4 °C/min to 230 °C (total run time of 28 min). The
transfer line from the oven to the mass spectrometer was
heated to 240 °C and the inlet to 230 °C. The mass
spectrometer was run in split mode, with a flow of
10 mL/min and a split ratio of 8. Chromatographic
separation was achieved using a 30 m × 0.25 mm ×
0.25 μm 70 % cyanopropyl polysilphenlyene-siloxane
TR-FAME column (Thermo Scientific) with 1.2 mL/
min helium at constant flow as carrier. Positive ion
mode data were collected after an initial 4 min delay
with three scans per second in the 50–650 m/z range.
Chromatograms were processed using the Xcalibur
software suite (version 2.2; Thermo Scientific). Individ-
ual peaks were integrated and subsequently normalised
to total peak intensity. Peaks were assigned based on
fragmentation patterns and matched to the National
Institute of Standards and Technology (NIST, USA) li-
brary. Peak identification was supported by comparing re-
tention times and fragmentation patterns to the Supelco
37-Component FAME Mix (Sigma-Aldrich) and to the
American Oil Chemists’ Society archive of methyl ester
derivatives (AOCS, USA).
Respirometry
Respirometry was performed on 2–5 mg saponin-
permeabilized soleus muscle fibre bundles at 37 °C using
Clark-type oxygen electrodes (Strathkelvin Instruments,
Strathkelvin, UK), essentially as described [23]. Briefly,
0.04 mM palmitoyl-carnitine and 5 mM malate were
supplied as substrate (LEAK state) before oxygen con-
sumption was stimulated by the addition of 2 mM ADP
(OXPHOS state). Muscle fibres were recovered from the
electrode chamber to allow normalisation of oxygen
consumption rates to dry muscle mass. For C2C12 stud-
ies, cells suspended in 500 μL of respiration medium
were added to the Clark-type electrode chambers for
analysis, along with 0.02 % w/v digitonin to permeabilize
cells, and respiration carried out as it was for muscle
fibres, with rates normalised to number of cells.
CPT1 activity and palmitate oxidation assays
Mitochondria were isolated from soleus muscle from
rats according to published protocols [48]. CPT1 activity
was determined in soleus muscle mitochondrial isolates
using 3H-carnitine according to previously published
protocols [49]. The assay buffer contained 117 mM
Tris–HCl, 0.28 mM reduced glutathione, 4.4 mM
MgCl2, 16.7 mM KCl, 2.2 mM KCN, 300 μM palmitoyl-
CoA, 5 mM carnitine, 4.4 mM ATP, 40 mg/L rotenone,
0.5 % BSA, and 1 μCi 3H-carnitine. The reaction was
initiated with the addition of 20 μL of mitochondrial ho-
mogenates and incubated for 8 min at 37 °C. The reac-
tion was then terminated by the addition of 60 μL of
HCl. The palmitoyl-3H-carnitine formed during the re-
action was separated according to previously published
protocols [50, 51] and the radioactivity counted to deter-
mine CPT1 activity. The reaction is linear in rats for
8 min at protein concentrations of <0.5 mg mitochon-
drial protein [46] and all assays were carried out within
these limits.
Palmitate oxidation rates were measured in soleus
muscle mitochondrial isolates using 14C-palmitate accord-
ing to previously published methods [52, 53]. Briefly,
modified Krebs-Ringer buffer (115 mM NaCl, 2.6 mM
KCl, 1.2 mM KH2PO4, 10 mM NaHCO3, 10 mM HEPES,
pH 7.4) supplemented with 5 mM ATP, 1 mM NAD+,
0.5 mM carnitine, 0.1 mM coenzyme A, 25 μM cyto-
chrome c, and 0.5 mM malate were incubated at 37 °C in
a 20 mL glass scintillation vial. A suspended microcentri-
fuge tube containing 150 μL of benzethonium hydroxide
were placed inside the vial to trap the 14CO2 produced
during the reaction. Mitochondria were added to the sys-
tem, which was then sealed with a rubber cap. The reac-
tion was initiated by the addition of 6:1 palmitate:BSA
complex (containing 1 μCi of 14C-palmitate) to a final
palmitate concentration of 100 μM via a syringe through
the rubber cap. The vial was incubated for 30 min at 37 °C
before termination with 50 μL of HClO4. The microcentri-
fuge tube containing the benzethonium hydroxide and
trapped 14CO2 was then removed, transferred to a scintil-
lation vial, and the radioactivity counted.
Enzyme analysis
Frozen tissues were powdered under liquid nitrogen
with a mortar and pestle and homogenized in potassium
phosphate buffer (100 mM KH2PO4, 5 mM EDTA, 0.1 %
Triton X-100, pH 7.2) using a polytron homogenizer.
HOAD activity was assayed according to a published
protocol [54]. The assay buffer contained 50 mM imid-
azole (pH 7.4), 0.1 mM acetoacetyl-CoA, 0.15 mM
NADH, and 0.1 % Triton X-100. NADH absorbance was
monitored at 340 nm for 3 min.
CS was assayed according to a previously published
protocol [55]. The assay buffer contained 20 mM Tris
(pH 8.0), 0.1 mM 5,5’-dithiobis-(2-nitrobenzoic acid)
and 0.3 mM acetyl-CoA. The reaction was initiated by
the addition of 0.5 mM oxaloacetate (omitted from con-
trols), and absorbance monitored at 412 nm for 3 min.
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PPAR binding assays
Frozen tissue was crushed using a liquid nitrogen-cooled
pestle and mortar, and homogenates prepared from
which the nuclear subcellular fraction was isolated using
a commercial kit (Cayman Chemical Company, MI,
USA). Ice-cold hypotonic buffer was added to crushed
tissue in a 5 μL:1 mg ratio. The solution was homoge-
nised using a polytron before being incubated on ice for
15 min. After incubation, samples were centrifuged at
1,000 × g for 10 min at 4 °C to pellet cell debris, and the
supernatant containing the cytosolic fraction transferred
to a pre-chilled micro-centrifuge tube. The pellet was re-
suspended in 500 μL hypotonic buffer and incubated on
ice. After 15 min, 50 μL 10 % Nonidet P-40 were added
and the samples centrifuged at 14,000 × g for 30 s at 4 °C.
The supernatant was combined with the cytosolic fraction
from the previous step and frozen at −80 °C. The pellet was
resuspended in 50 μL ice-cold extraction buffer, vortexed
vigorously for 15 s and subsequently rocked on a shaking
platform for 15 min on ice. The vortexing and shaking were
repeated, and the samples centrifuged at 14,000 × g for
10 min at 4 °C. The supernatant was transferred to pre-
chilled tubes, flash frozen and stored at −80 °C until use. A
small aliquot was used to quantify protein concentration
using a spectrophotometer.
PPARα and β/δ transcriptional activity were assayed in
nuclear extracts using a commercial transcription factor
kit (Cayman Chemical Company, MI, USA). The wells
of a plate were coated by a double-stranded DNA
(dsDNA) sequence containing the peroxisome prolifera-
tor response element. By utilising nuclear extracts, only
binding of proteins within the nucleus are quantified,
which effectively represents activated PPARs. Nuclear
extracts and all kit reagents were allowed to equilibrate
to room temperature before use. To the blank and non-
specific binding wells 100 μL of transcription factor
assay buffer were added. In the competitor dsDNA wells,
80 μL transcription factor assay buffer were added
followed by 10 μL PPAR competitor dsDNA. In the posi-
tive control wells, 90 μL of transcription factor assay
buffer were added followed by 90 μL of positive control.
Finally, 90 μL of transcription factor assay buffer were
added to each sample well followed by 10 μL nuclear ex-
tract. The plate was covered and incubated overnight at
4 °C without agitation. The wells were then emptied and
washed five times with 200 μL of wash buffer, with care
taken on the final wash to remove residual buffer. To
each well, except the blanks, 100 μL of either PPARα or
PPARβ/δ primary antibody solution were added and the
plate covered and incubated for 1 h at room temperature
without agitation. The wash step was repeated as above
and any residual wash buffer carefully removed. To each
well, except the blanks, 100 μL of horseradish peroxidase
(HRP)-conjugated secondary antibody were added and
the plate covered and incubated for 1 h at room
temperature without agitation. The wells were washed
with 200 μL of wash buffer as above, before 100 μL of
developing solution was added and the plate incubated
for 30 min at room temperature with gentle shaking.
After incubation, 100 μL stop solution were added to
each well and the absorbance read at 450 nm within
5 min.
Gene expression analysis
Total RNA was purified from crushed, frozen muscle
using an RNeasy Mini Kit (QIAgen) according to the
manufacturer’s specifications. RNA concentration was
quantified at 260 nm using a SmartSpecPlus spectropho-
tometer (Bio-Rad). For analysis of steady-state mRNA
levels, the relative abundance of transcripts of interest was
assessed by quantitative-PCR in SYBR Green FastStart
Universal Master Mix (Applied Biosystems) with a StepO-
nePlus detection system (Applied Biosystems). QuantiTect
primer assays for rat Ppara and Pparbd were obtained
from QIAgen. Expression levels were normalized to Actb
using the ΔCT method, and subsequently to ‘normoxia/
chloride’ group in the hypoxia study and to the ‘control’
group in the dose–response study, to give fold-changes.
For gene analysis in C2C12 cells, RNA extraction was
performed as above, with the single difference being that
450 μL of lysis buffer were added directly to the wells,
and subsequently pipetted onto the spin columns for
purification. Production of cDNA and RT-qPCR analysis
of Myod, Tnni1, Tnni2, CptIb, Acadl, Hadh, Ucp3, Cycs,
and Ndufs1 expression proceeded as above, using
QuantiTect primer assays obtained from QIAgen.
Immunoblotting
Immunoblotting for citrate synthase, PGC-1α and malonyl-
CoA decarboxylase was performed on soleus muscle lysates
according to published protocols [56]. Membranes were in-
cubated in primary antibody solution containing 1:1000
rabbit polyclonal IgG raised against CS, PGC-1α or MCD
(all Abcam, UK) for 2 h at room temperature (CS and
PGC-1α) or overnight at 4 °C (MCD). After washing with
TBS-T for 2 h with a solution change every 15 min, mem-
branes were incubated in secondary antibody solution con-
taining 1:1750 goat anti-rabbit IgG, conjugated to HRP for
1 h, before visualisation using ECL-plus and quantification
as previously described [56].
CPT1B enzyme-linked immunosorbent assay
CPT1B protein concentration was measured using a
commercial mouse CPT1B ELISA (MyBioSource, USA),
according to the manufacturer’s specifications, in cell ly-
sates prepared as detailed above. Samples (diluted 20
times) and standards were incubated in duplicate on a
96-well plate containing an immobilised antibody to
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mouse CPT1B for 2 h at 37 °C. After unbound sub-
stances were washed away, biotin conjugated to a sec-
ondary antibody raised against CPT1B was added, and
the plate incubated for 1 h at 37 °C. After further
washes, a streptavidin-HRP conjugate was added and in-
cubated for 1 h at 37 °C, followed by further washes to
remove unbound conjugate. A substrate solution was
then added to the wells and incubated, protected from
light, for 30 min at 37 °C. Diluted HCl was added to stop
the enzymatic reaction, and finally the optical density
was measured at 450 nm with readings at 540 nm sub-
tracted to account for optical imperfections in the plate.
Data were collated and normalised to total protein in
the original sample.
Statistics
Results are expressed as mean ± SEM. Analysis of variance
(ANOVA) was used to determine significant differences
across the four groups of the hypoxia and dose–response
studies. Data were collated in Excel before 1- or 2-way ana-
lysis of variance (ANOVA) was used to determine signifi-
cant differences across experimental groups (Graphpad,
Instat). Bonferroni post-hoc analysis was used for multiple
analysis of selected groups, where appropriate. Differences
were considered significant when P <0.05.
Availability of supporting data
All data supporting the results of this article are avail-
able in an online Additional file 3.
Additional files
Additional file 1: Figure S1. Muscle differentiation marker expression
in C2C12 myoblasts cultured and differentiated over 6 days in the
presence of 0, 50 and 500 μM nitrate, and (A) in the presence and
absence of sGCi (1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one (ODQ),
1 μM) and (B) in the presence and absence of PGKi (KT5823, 1 μM). Data
are represented as mean ± SEM, n = 4 repeats per condition. (PDF 52 kb)
Additional file 2: Figure S2. Ucp3, Acadl and Cpt1b expression in
C2C12 myoblasts cultured and differentiated over 6 days in the presence
of 500 μM nitrate. Data are represented as mean ± SEM, n = 3 repeats per
condition. *** P ≤0.001. (PDF 24 kb)
Additional file 3: Supporting data. (XLSX 45.3 kb)
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eNOS: endothelial nitric oxide synthase; FA: fatty acid; HIF: hypoxia-inducible
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